958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

• John Haanen,
• Alexander Desuki,
• Andreas Mackensen,
• Ugur Sahin,
• Christian Koenecke,
• Winfried Alsdorf,
• Eva Wagner-Drouet,
• Daniel Heudobler,
• Peter Borchmann,
• Erol Wiegert,
• Catrine Schulz,
• Benjamin Rengstl,
• Liane Preussner,
• Oezlem Tuereci

Affiliations

John Haanen

Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Alexander Desuki

5University Medical Center Mainz, Mainz, Germany

Andreas Mackensen

1 Department of Internal Medicine 5 - Hematology and Clinical Oncology, Friedrich Alexander University (FAU), Erlangen, Germany

Ugur Sahin

1BioNTech SE, Mainz, Germany

Christian Koenecke

2Hannover Medical School, Hanover, Germany

Winfried Alsdorf

4University Medical Center Eppendorf, Hamburg, Germany

Eva Wagner-Drouet

5University Medical Center Mainz, Mainz, Germany

Daniel Heudobler

6University Hospital Regensburg, Regensburg, Germany

Peter Borchmann

7University Hospital of Cologne, Cologne, Germany

Erol Wiegert

8Bexon Clinical Consulting, Upper Montclair, USA

Catrine Schulz

9BioNTech SE, Mainz, Germany

Benjamin Rengstl

9BioNTech SE, Mainz, Germany

Liane Preussner

9BioNTech SE, Mainz, Germany

Oezlem Tuereci

9BioNTech SE, Mainz, Germany